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Abstract
Background: Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response
rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human
patients, responses to checkpoint blockade therapy correlate with tumor mutation load, and intrinsic resistance
associates with pre-treatment signatures of epithelial mesenchymal transition (EMT), immunosuppression, macrophage
chemotaxis and TGFβ signaling.
Methods: To facilitate studies on mechanisms of squamous cell carcinoma (SCC) evasion of checkpoint blockade
immunotherapy, we sought to develop a novel panel of murine syngeneic SCC lines reflecting the heterogeneity of
human cancer and its responses to immunotherapy. We characterized six Kras-driven cutaneous SCC lines with a range
of mutation loads. Following implantation into syngeneic FVB mice, we examined multiple tumor responses to α-PD-1,
α-TGFβ or combinatorial therapy, including tumor growth rate and regression, tumor immune cell composition,
acquired tumor immunity, and the role of cytotoxic T cells and Tregs in immunotherapy responses.
Results: We show that α-PD-1 therapy is ineffective in establishing complete regression (CR) of tumors in all six SCC
lines, but causes partial tumor growth inhibition of two lines with the highest mutations loads, CCK168 and CCK169. α-
TGFβ monotherapy results in 20% CR and 10% CR of established CCK168 and CCK169 tumors respectively, together
with acquisition of long-term anti-tumor immunity. α-PD-1 synergizes with α-TGFβ, increasing CR rates to 60%
(CCK168) and 20% (CCK169). α-PD-1 therapy enhances CD4 + Treg/CD4 + Th ratios and increases tumor cell pSmad3
expression in CCK168 SCCs, whereas α-TGFβ antibody administration attenuates these effects. We show that α-TGFβ
acts in part through suppressing immunosuppressive Tregs induced by α-PD-1, that limit the anti-tumor activity of
α-PD-1 monotherapy. Additionally, in vitro and in vivo, α-TGFβ acts directly on the tumor cell to attenuate EMT, to
activate a program of gene expression that stimulates immuno-surveillance, including up regulation of genes encoding
the tumor cell antigen presentation machinery.
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Conclusions: We show that α-PD-1 not only initiates a tumor rejection program, but can induce a competing TGFβ-
driven immuno-suppressive program. We identify new opportunities for α-PD-1/α-TGFβ combinatorial treatment of
SCCs especially those with a high mutation load, high CD4+ T cell content and pSmad3 signaling. Our data form the
basis for clinical trial of α-TGFβ/α-PD-1 combination therapy (NCT02947165).
Keywords: Checkpoint blockade, Squamous cell carcinoma, Tumor mutation load, α-TGFβ /α-PD-1 combinatorial
immunotherapy, Tregs, pSmad signaling, Epithelial mesenchymal transition (EMT)
Background
Antibody-based therapies targeting T cell checkpoint re-
ceptors, CTLA-4 and PD-1, have ushered in a revitalized
era of cancer immunotherapy (IMT). α-PD-1 mediated
immune checkpoint blockade is now first line therapy
for melanoma and PD-L1+ lung cancer, and second line
therapy for squamous cell carcinoma of the head and
neck (SCC-HN), and other tumor types [1, 2]. However,
response rates vary across tumor types, and even within
the most responsive cancer, namely melanoma, durable
responses occur in only a minority of patients and 25%
of responding patients eventually relapse [1, 2]. Import-
antly, α-PD-1 therapy can paradoxically accelerate tumor
growth in certain patients by mechanisms that are pres-
ently unclear [3–5]. Many efforts are therefore underway
to increase α-PD-1 response rates, identify mechanisms
of intrinsic and acquired α-PD-1 drug resistance, predict
potential responders or super-progressors prior to treat-
ment, and investigate new combinatorial drug regimens.
A major correlate of clinical response to immune
checkpoint blockade is the quantitative load of somatic
non-synonymous single nucleotide mutations (NS-SNMs)
[6]. We therefore utilized a mouse model of chemically-in-
duced cutaneous squamous cell carcinomas (cSCC) which
have a range of somatic mutations that mimic the
NS-SNM mutation burden of environmentally-induced hu-
man cancers [7]. In this cSCC model, endogenous Hras or
Kras oncogenic drivers are chemically-activated by local
7,12-dimethylbenz (a) anthracene (DMBA) treatment that
induces transversion mutations resulting primarily in
KrasG13R or HrasQ61L somatic mutations [7]. Subsequent
tumor outgrowth depends on repeated exposure to the
inflammation-inducing phorbol ester, 12–0-tetradecanoyl--
phorbol-13 acetate, thus mimicking the important role of
chronic inflammation in development of many human can-
cers. This two-step chemical carcinogenesis model has been
thoroughly characterized with respect to dominant driving
genetic events, evolution of the mutational landscape as
carcinomas progress from initiation through benign and
malignant stages, and in vivo epithelial-to-mesenchymal
transition (EMT) and metastasis [7–9]. The biphasic activ-
ities of TGFβ during tumor progression and synergy be-
tween Ras and TGFβ have also been intensively studied
using this model [8, 10–12].
In humans, intrinsic resistance of melanoma to
α-PD-1 therapy has been associated with a transcrip-
tomic signature enriched for markers of EMT, immune
suppression and macrophage chemotaxis [13], all of
which can be driven by TGFβ signaling [11, 12, 14, 15].
Moreover, recent genomic and transcriptomic analysis of
a large panel of human urothelial carcinomas showed a
positive association between tumor mutation load
(TML) and clinical response to the checkpoint inhibitor,
atezolizumab, an antibody that blocks a ligand for the
PD-1 receptor, PDL-1, [16]. This study also demon-
strated that in the subset of bladder carcinomas that are
“immune-excluded”, the strongest pre-treatment transcrip-
tomic signature that associates with failure to respond to
subsequent atezolizumab therapy is enrichment for a fibro-
blastic signature with high expression of TGFβ signaling
genes particularly TGFB1 and TGFBR2 [16]. This, and an-
other study of colon carcinomas [17], concluded that TGFβ
signaling within cancer-associated fibroblasts (CAFs) forms
a barrier to intra-tumoral penetration of immune cells that
can be alleviated by blockade of TGFβ signaling, resulting
in synergy between α-PDL-1 and α-TGFβ therapy. Add-
itional studies have reported additive, synergistic or redun-
dant anti-tumor interactions between TGFβ signaling and
PD-1/PD-L1 blockade in different model systems in vitro
and in vivo [18–22].
Herein, we generated a number of cutaneous SCC tumor
lines derived from chemically-induced primary carcinomas
and from the low mutation load genetically-engineered
mouse model (GEMM), Lgr5-Cre-ERT2 x KrasG12D-LSL
[23]. In agreement with observations on human cancers
[6, 16, 24], we found that the SCC lines with highest
TMLs are the most responsive to α-PD-1, but even in
these high TML SCCs, α-PD-1 therapy rarely achieves
complete regression (CR). We find that in high TML
SCCs, α-PD-1 therapy further elevates tumor cell
pSmad3 signaling and increases the fraction of CD4+ T
cells that are immunosuppressive Tregs (Foxp3 + CD25+),
thus restraining the anti-tumor immune response to this
checkpoint inhibitor, but a combination of α-TGFβ with
α-PD-1 synergistically enhances anti-tumor responses. We
show that drug synergy is driven by induction, not only of
T effector cell activation by α-PD-1, but of a competing
TGFβ-driven immunosuppressive program that acts to
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induce tumor cell EMT and polarization of CD4+ T cells
to blunt the response to α-PD-1 therapy.
Methods
Detailed methods and statistical tests can be found in
Additional file 1: Supplementary Methods.
Results
α-PD-1 monotherapy elevates immunosuppressive Tregs
in chemically induced squamous carcinomas
We first generated a panel of highly aggressive Kras-dri-
ven cSCC, four derived from DMBA-initiated KrasG13R
mutant tumors and two derived from tumors of the
GEMM, Lgr5-Cre-ERT2 x KrasG12D-LSL [23], all on the
FVB/NJ strain background. Whole exome sequencing
(WES) revealed that the chemically induced tumor lines
represent a range of mutation loads, from ~ 50 to 300
NS-SNMs per exome (Fig. 1a, Additional file 2: Table S1),
similar to that of human cancer [6, 25], but the two
GEMM-derived tumor lines that are driven by a transgenic
KrasG12D oncogene had less than 40 NS-SNMs per exome
(Fig. 1a, Additional file 2: Table S1).
In most other syngeneic mouse models, α-PD-1 as
monotherapy has no effect on primary tumor out-
growth [26, 27]. Consistent with this, when adminis-
tered intra-peritoneally (ip) to mice with established
tumors (Fig. 1b), most of the SCC lines show little or
no tumor growth response to α-PD-1, including the
two GEMMs and three of the chemically-induced
cSCCs, CCK62, CCK166 and CCK169 (Fig. 1 c-e, and
Additional file 3: Figure S1). In contrast, CCK168,
which has the highest TML, shows a significant delay
in tumor outgrowth in response to α-PD-1 monother-
apy (Figs. 1f ), This finding is compatible with data from
human clinical trials that show a positive relationship
between TML and response to checkpoint blockade in-
hibitors [6, 16, 24].
We next investigated changes in intra-tumoral im-
mune cell subsets in CCK168 tumors, seven to eight
days after initial α-PD-1 treatment, at a time when
a b
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Fig. 1 α-PD-1 effects on tumor-growth of chemically-induced and GEMM-derived SCCs. a Total NS-SNV loads of Kras-driven SCCs, determined by
WES analysis. The panel includes four chemically-induced (CCK) and two GEMM-derived (GEK) SCCs, b Scheme for syngeneic tumor generation
and drug therapy: After implantation of 1.5 × 104 tumor cells by unilateral dorsolateral subcutaneous injection, tumors grew for 14 days until they
reached ≥5 mm diameter. Mice were then treated with control IgGs or α-PD-1 drugs injected intraperitoneally (ip) into the contralateral side, with
three drug administrations, each four days apart (considered days 0, 4 and 8). c-f) Tumor growth of the indicated tumor lines with or without α-
PD-1 therapy was measured at least every other day from the time of first drug administration. Red arrows indicate timing of drug administration
(see Additional file 3: Figure S1 for GEK1428, and CCK62 growth curves), c-e) mean tumor growth of 7–10 mice per arm. ** = p < 0.01 (Fisher’s
Exact test)
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responsive tumors begin to diminish in size (see Fig. 1f ).
Immunohistochemical (IHC) analysis suggested only a
slight increase in CD45+, CD3+, and CD8+ T cell infil-
tration into CCK168 tumors after α-PD-1 monotherapy,
and the majority of infiltrating immune cells did not
fully penetrate the tumor core but were located within
the outer cortex of the tumor parenchyma (Fig. 2a).
Using multicolor flow cytometry, we found that around
50% of CD45+ tumor infiltrating leukocytes were Cd11b+
myeloid cells (Fig. 2b), and CD4+ T cells were the most
common T lymphocyte cell type in IgG-treated CCK168
control carcinomas. Total CD4+ T cells constitute 20%
of tumor infiltrating CD45+ leukocytes (Fig. 2c), whereas
CD8+ cytotoxic T cells contribute only 5% of the
leukocyte population (Fig. 2d). α-PD-1 therapy caused a
significant decrease in MHCII+ myeloid cell numbers
(Fig. 2b), driven by a reduction in the major myeloid
population of Ly6Clo tumor associated macrophages
(TAMs), that are considered immuno-suppressive [28].
As determined by flow cytometry, α-PD-1 monother-
apy did not significantly affect tumor infiltration of total
CD4+ (Fig. 2c) or CD8+ T cells (Fig. 2d) but, unexpect-
edly, it consistently and significantly skewed the balance
between CD4 + CD25 + Foxp3+ Tregs and CD4 + Foxp3-
Th cells (Fig. 2 e-g). Bearing in mind the prominence of
CD4+ T cells within the lymphocyte population of
CCK168 tumors, we considered that the enhanced CD4
+ Treg to CD4 + Teff (effector) ratio (Fig. 2g), and the
presumed change in cytokine profile from inflammatory
to immunosuppressive T cells, might contribute in part
to reduced penetration of cytotoxic CD8+ T cells into
the tumor core.
α-TGFβ monotherapy initiates durable CR of SCCs and
synergizes with α-PD-1 therapy
iTreg differentiation is driven by the master transcrip-
tion factor, Foxp3, which is transcriptionally activated by
TGFβ effectors, pSmad3 and Smad4 [29], we thus postu-
lated that suppression of Treg activation through block-
ade of TGFβ ligands might enhance α-PD-1 tumor
responses. Moreover, several recent studies gave cre-
dence to the possibility of synergy between TGFβ inhib-
ition and blockade of the PD-1/PDL-1 axis [16–19]. We
therefore utilized a pan-TGF-β neutralizing antibody,
XPA-42-068 [30] that blocks all three activated TGFβ li-
gands, to test for drug synergy in the various SCC lines.
We tested each of the six Kras-driven tumor lines for re-
sponses to the combination of α-PD-1 and α-TGFβ anti-
bodies (Fig. 3a). Both CCK168 and CCK169, each with
NS-SNM loads greater than 200 (Fig. 1a), showed highly
heterogeneous tumor responses following administration
of both drugs, with cases of progressive disease as well
as partial or complete tumor responses (Fig. 3 a-d). The
other SCC lines, all of which have NS-SNM loads less
than 100 (Fig. 1a), lacked responses to the drug combin-
ation (Fig. 3a). Surprisingly, the α-TGFβ antibody given
as monotherapy showed significantly better anti-tumor
efficacy than α-PD-1 monotherapy for CCK168 tumors
(Fig. 3 b, c), with more than 20% of established CCK168
tumors showing durable CR after α-TGFβ monotherapy
(Fig. 3c). A similar trend was observed in the CCK169
model (Fig. 3d). Importantly, α-TGFβ synergizes with
α-PD-1 resulting in 60% overall long-term survival in
the CCK168 model and 20% CR for CCK169 (Figs. 3
b-d, Additional file 3: Figure S2).
To test the requirement for adaptive immune responses
in eliciting SCC tumor regression, we depleted cytotoxic
CD8+ T cells using an α-CD8a antibody that induces
antibody-dependent cellular cytotoxicity (ADCC). We
found that the effect of combinatorial therapy on CCK168
tumors was completely abolished (Fig. 3e). Moreover, con-
sistent with ongoing immune surveillance, CCK168 tumor
growth accelerated after CD8+ T cell depletion, regardless
of the presence of immunotherapy drugs (Fig. 3e). It is
possible that some of the effects of the α-CD8a antibody
may be mediated by depletion of CD8+ DCs that play a
unique role in cross-presentation of tumor antigens on
MHC class I [31]. Regardless, the data support the conclu-
sion that α-TGFβ-induced tumor regression is predomin-
antly mediated through adaptive immunity.
Finally, we compared the efficacy of the α-pan-TGFβ
antibody with that of a clinical lead, currently in phase
Ib trial in combination with α-PD-1. This antibody, XPA-
42-089, that blocks TGFβ1 and TGFβ2, but cannot bind
and block TGFβ3, was as efficacious as XPA-42-068 as
monotherapy or when combined with α-PD-1 (Fig. 3f).
TGFβ3 therefore does not appear to play a major immuno-
suppressive role in the CCK168 SCC model.
α-TGFβ drives long-term tumor immunity against
KrasG13R driven SCCs
Since CD8+ cytotoxic T cells drive tumor rejection, we
investigated long-term immunity to tumor re-challenge.
Indeed, parental CCK168 cells failed to grow when im-
planted into “CCK168-cured” mice (n > 24) despite ro-
bust growth when implanted into tumor-naïve mice
(n = 3–5 tumor-naïve mice per test Fig. S3), suggesting
activation of immune memory to CCK168 by TGFβ
blockade. This immune memory of CCK168-cured mice
persists even 18 months beyond the last drug dose. Intri-
guingly, CCK169 or CCK166 cells, when implanted into
“CCK168-cured” mice, also failed to grow despite robust
growth in tumor-naïve mice (Fig. S3). This was despite
the latter tumor line showing complete resistance to de
novo α-TGFβ/α-PD-1 combination therapy (Fig. 3a).
WES analysis revealed that the chemically-induced
KrasG13R mutation was the only potential neoantigen
shared between CCK166, CCK168 and CCK169
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(Additional file 4: Table S2), raising the possibility that,
in this model, KrasG13R is a dominant neoantigen driving
immune rejection. Notably, in human cancer, mutation of
KRAS-G12D has been shown to generate a neoantigen
that elicits CD8+ cytotoxic T cell responses [32].
Supporting the concept that KrasG13R encodes a domin-
ant neoepitope in the CCK168 model, a chemically-induced
HrasQ61L-driven SCC, CCH85 (214 NS-SNMs), grew
equally well when implanted into either tumor-naive or




Fig. 2 Alteration in tumor infiltrating leukocyte profiles in response to α-PD-1 therapy. Tumors, generated according to the scheme in Fig. 1b,
were harvested 7 days after the first drug treatment and analyzed by (a) immunohistochemistry or (b-g) 11-color flow cytometry. a Immunohistochemical
staining shows CD3+ total T cells, CD8a + cytotoxic T cells and CD45+ immune cells in the non-responsive tumor line, CCK62, and in the responsive tumor
line, CCK168. b-g Flow cytometric analysis of CCK168 immune cell subsets in response to α-PD-1 therapy: b CD11b +Gr1-Ly6C-Ly6Clo myeloid cells, c total
CD4+ T cells, d cytotoxic CD8+ T cells, e CD4+ CD25 + Foxp3+ Treg cells, f CD4 + Foxp3-CD25- Th cells, g ratio of CD4+ Th/Treg cells. Cell numbers
shown are relative to 100, 000 CD45+ immune cells. Representative data of ≥ three biological replicates. Scale bars in (a) represents 50 μM in upper panels
and 200 μM in lower panel. * = p < 0.05; ** = p < 0.01; *** = p < 0.001: Mann Whitney U test
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“CCK168-cured” mice supported robust tumor growth of
implanted KrasG12D-driven GEK1425 or GEK1428 tumor
cells, further supporting a requirement for the KrasG13R
neoepitope in driving tumor rejection. However, three other
“CCK168-cured” mice rejected outgrowth of GEK1425 or





Fig. 3 α-TGFβ and α-PD-1 synergize in eliciting tumor rejection in a CD8a + cell-dependent manner. a Growth curves of each of the six SCC lines,
as indicated, after treatment with control IgG or α-TGFβ/α-PD-1 combination therapy on days 0, 4 and 8 (n = 8–10 mice per arm). Tumors were
measured every other day after tumor implantation and therapy (see Fig. 1b). Summary of tumor responses for CCK168 (b) and CCK169 (d), and
overall survival for CCK168 (c) following treatment on days 0, 4 and 8 with control IgG, α-PD-1, α-TGFβ or combination therapy. In (b) and (d),
individual tumors were classified as complete responders (CR), partial responders (PR), or progressive disease (PD), according to their growth
characteristics (CR, tumor eradicated with no regrowth; PR, tumor shrinkage ≥30%; PD, no effect of drugs compared to control IgG). For each
drug arm, the percentages of total tumors within each response group are shown. n = 10 mice per arm per experiment, n = 3 independent
experiments. c Kaplan Meier survival plot for mice bearing CCK168 tumors, after treatment on days 0, 4 and 8 with the indicated drugs. 2000
mm3 tumor size was used as the cut off for survival. e Average CCK168 tumor growth curves following treatment with α-PD-1/α-TGFβ
combination therapy versus isotype control IgGs in mice with or without CD8+ T cell depletion. Animals were treated as in Fig. 1b, except that
24 h prior to the first therapeutic drug dose, mice received ip injection of CD8a + cell-depleting antibody or isotype matched control IgG. f)
CCK168 tumor-bearing mice were administered one of six IgG combinations, either human α-pan-TGFβ IgG2 (XPA.42.068), human α-TGFβ1/β2
IgG2 (XPA.42.089) or human α-keyhole limpet hemocyanin as control IgG2, together with rat α-PD-1 IgG2 or rat IgG2 control, on days 0, 4 and 8.
Average tumor volume (mm3) +/− SD. * = p < 0.05; ** = p < 0.01; *** = p < 0.001: Fisher’s exact test (b), Gehan-Breslow-Wilcoxon test (c), Student’s
test (e, f)
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tumor epitopes, shared between these KrasG12D-driven
tumor lines and KrasG13R-driven CCK168, can also elicit
tumor rejection. Such common epitopes in these Kras-dri-
ven tumors may result from quantitatively abnormal
protein expression or splicing [18, 33] that would be
undetectable by WES analysis. Further studies would
be required to demonstrate that KrasG13R is a dom-
inant neoantigen in this mouse model.
Synergy between α-TGFβ and α-PD-1 is mediated in part
through effects on Tregs
We next sought to validate the possible mechanisms
contributing to synergy between α-TGFβ and α-PD-1
antibodies in immunotherapy. IHC and flow cytometry
analyses revealed that combinatorial therapy of CCK168
tumors with the two therapeutic antibodies caused a
large increase in CD45+ leukocytes cells compared to ei-
ther monotherapy (Fig. 4a, b). Tumor infiltration of
cytotoxic CD8+ T cells was only marginally increased by
α-PD-1 treatment, but the drug combination generated
a robust CD8+ T cell influx (Fig. 4a, c). Furthermore,
α-TGFβ or α-PD-1 monotherapy elevated the percentage
of CD8+ T cells that express markers of late T cell differ-
entiation and partial T cell exhaustion, ICOS and
CTLA4 (Fig. 4d, Additional file 3: Figure S4), that have
also been associated with active anti-tumor responses in
human tumors [34]. However, even after combinatorial
therapy, fewer than 50% of CD8+ T cells expressed these
markers (Fig. 4d, Additional file 3: Figure S4). In con-
trast, the majority (70–90%) of CD4+ T cells, and
specifically > 90% of CD4+ Tregs, expressed both
ICOS and CTLA4 (Figs. S4, S5), suggesting that most
intratumoral Tregs in CCK168 control tumors are in
an activated state.
Importantly, α-TGFβ significantly reduced relative
Treg levels (Fig. 4f ), and variably enhanced CD4 + Th/
Treg and CD8 + T/Treg ratios, in some cases up to forty
fold, particularly in responding tumors (Fig. 4 g,h). In
contrast to α-PD-1 monotherapy (Figs. 2a), α-TGFβ
antibodies or the drug combination resulted in infil-
tration of total CD45+ and CD8a + T cells into the
tumor core (Fig. 4a).
The myeloid MHCII+ antigen presenting cell popula-
tion was substantially reduced by either drug given as a
single agent, including reduced TAM and DC levels
(Figs. 2 b, 4i-k, Additional file 3: Figure S6). Additionally,
each monotherapy caused a slight but significant increase
in the ratios of Ly6Chi/Ly6Clo and CD11bhiCD11clo/
CD11bloCD11chi [28] TAMs (Fig. S6), suggesting a shift in
the balance from immunosuppressive towards inflamma-
tory TAMs, however, there was no synergistic effect of
combinatorial therapy. Th17 T cell, natural killer cell and
CD103+ DC numbers were all low and not significantly
affected by drug treatment in CCK168 (not shown). This
does not however exclude the possibility that these cell
types play an important role in tumor responses. Migra-
tory CD103+ DCs, for example, although a rare popula-
tion within tumors, are essential for efficient antigen
presentation within draining lymph nodes [28].
α-TGFβ antibodies thus have multiple effects on
lymphocyte and myeloid cell molecular phenotypes, but
the over-arching factors that correlate with synergism
between α-TGFβ and α-PD-1 appear to be combinatorial
increases in CD8+ cytotoxic T cells and reversal, by
α-TGFβ, of the unfavorable CD4+ Treg/Th balance in-
duced by α-PD-1 monotherapy. In order to demonstrate
that Tregs are biologically active in CCK168 tumors, and
limit tumor eradication by α-PD1, we depleted CD4 +
CD25+ Tregs using an α-CD25 antibody engineered to
optimize intra-tumoral ADCC of CD25+ Tregs [35]. Within
24 h of systemic α-CD25 administration, intra-tumoral Treg
levels (CD4+ Foxp3+ and CD4+CD25+) were reduced ap-
proximately 50% within CCK168 tumors (Additional file 3:
Figure S7). Treg depletion alone, by α-CD25 treatment, had
little effect on CCK168 tumor regression. Thus Tregs can-
not be the only cellular target responsible for α-TGFβ-in-
duced tumor regression in the absence of α-PD-1.
Nevertheless, α-CD25 treatment exhibited significant syn-
ergy when combined with α-PD-1 (Fig. 5a), demonstrating
that Tregs are functional and play a major role in restricting
the anti-tumor activity of α-PD-1 in the CCK168 model.
Combination of α-TGFβ therapy with α-CD25 Treg deple-
tion shows a trend towards better anti-tumor activity than
either treatment alone, but this effect did not reach statis-
tical significance (Fig. 5b). Taken together, these data sup-
port the concept that α-TGFβ acts via both Treg-dependent
and -independent mechanisms to elicit tumor rejection.
α-PD-1 therapy enhances intra-tumoral TGFβ/pSmad3
signaling within CCK168 tumor cells
To investigate which tumor cell types are responsive to
TGFβ, we assessed pSmad3 immuno-fluorescence stain-
ing of tumor sections. Smad3 is a direct substrate for the
transmembrane TGFβ type I receptor kinase and thus a
marker of TGFβ pathway activation. In control tumors,
we found high pSmad3 signaling in the majority of cells
of the tumor parenchyma, with a heterogeneous staining
pattern across each tumor, and variable expression be-
tween tumors (Fig. 6 a-d). In contrast, CD8+ cytotoxic T
cells and CD163+ macrophages showed no pSmad3
staining (not shown). Unexpectedly, in two independent
experiments (n = 3–5 tumors per arm per experiment),
α-PD-1 therapy significantly increased pSmad3 levels
over that observed in the IgG control group (Fig. 6 a-c,
Additional 3: Figure S8). Both basal and α-PD1-induced
pSmad3 were largely eliminated by α-TGFβ therapy
(Fig. 6 b, c, and Additional file 3: Figure S8). As early
as 2 h following ip injection of α-TGFβ antibodies
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(Fig. 6 f ), pSmad3 staining was downregulated in the
periphery but not within the core of the tumor paren-
chyma relative to that observed in IgG or α-PD-1-treated
tumors (Fig. 6a-f). Eight days (two doses) following
initiation of α-TGFβ monotherapy under the standard
protocol (Fig. 1b), pSmad3 downregulation was extensive
across the entire tumor, including the tumor core
(Fig. 6g, h). The magnitude of this decrease was
Fig. 4 Immunophenotyping of CCK168 tumors in response to α-PD-1 and α-TGFβ therapy. a-k) CCK168 tumor cells were implanted sc into FVB
mice according to Fig. 1b. After two drug doses on day 0 and 4, when some tumors began to show evidence of shrinkage, all tumors were
harvested and analyzed by (a) immunohistochemistry or (b-k) multicolor flow cytometry. a Representative images of CD8a and CD45
immunohistochemistry for tumors from each of the four drug arms. Six to seven tumors were analyzed per drug arm per stain. Scale bar
represents 50 uM. (b-k) Flow cytometry analysis shows increases in b CD45+ cells per live tumor cell, c CD8+ cytotoxic T cells per CD45+
immune cells and d increases in percentage of ICOS+ expressing CD8+ T cells. e α-PD-1 or α-TGFβ monotherapy elevates total CD4+ T cells with
no additive effect. f α-TGFβ monotherapy neutralizes α-PD-1 induction of Tregs and, in combination therapy, reduces Treg levels to below
baseline. g heterogeneous increase in CD4 + Th/CD4 + Treg ratio by α-TGFβ, h synergistic induction of CD8+/Treg ratios by α-PD-1 and α-TGFβ.
The latter increased six to 40 fold in response to combinatorial therapy. (i) MHCII+CD11b + and (j) MHCII+CD11c +myeloid cells diminish as a
percentage of total CD45 + cells following α-PD-1 or α-TGFβ therapy. k The ratio of mature T cells (CD4+ plus CD8+ cells) per CD11b myeloid cell
(CD45 + Ly6G-CD11b +MHCII+) increases after combinatorial therapy. Flow cytometry data are representative of two to seven independent
experiments for each cell type. * p < 0.05; ** p < 0.01; *** p < 0.001: Mann Whitney U test
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variable between tumors and generally associated with
evidence of tumor regression.
TGFβ induces EMT and reduces expression of tumor cell
antigen presentation genes in CCK168 cells
In the mouse skin model of chemical carcinogenesis,
TGFβ induces reversible EMT of tumor cells [8, 12] to
promote tumor cell invasion and metastasis [11]. Indeed,
even in CCK168 cells that are already spindle in phenotype,
in vitro TGFβ treatment further stimulates EMT, generat-
ing larger more fibroblastoid cells, and this phenotypic
switch is blocked by α-TGFβ (Fig. 6,i-m). In vivo, histo-
logical and pSmad3 immunofluorescence analysis of
CCK168 tumors eight days following initiation of immuno-
therapy, suggests drug-induced changes in EMT (Fig. 6 and
S9). All tumors were histologically heterogeneous, and both
control and α-PD-1-treated tumors contained swathes of
large, overtly fibroblastoid spindle tumor cells expressing
high pSmad3 at both the tumor periphery and throughout
the tumor (Figs. 6 e, Additional file 3: Figure S9). In α-
TGFβ-treated tumors this overtly spindle phenotype was
somewhat attenuated (Fig. S9), as previously observed in
E4-derived SCCs after treatment with a small mol-
ecule TGFβR1 inhibitor [36]. Thus, aspects of reversible
EMT observed in vitro, are also seen after αTGF-β ther-
apy in vivo.
EMT involves large-scale changes in the global tran-
scriptional program as cells transition from epithelial to
fibroblastoid. To determine possible implications of
these changes to innate tumor cell immunity, we investi-
gated the effects of TGFβ or α-TGFβ on expression of
genes encoding the antigen presentation machinery in
CCK168 cells in vitro. Indeed, TGFβ treatment suppressed
expression of Mhc1, B2m, Tap1 and Tap2, whereas α-TGFβ
treatment reversed these effects (Fig. 6n). Such molecular
changes might contribute to the ability of cytotoxic T
cells to recognize and destroy cancer antigen-expressing
tumor cells.
Heterogeneous responses of CCK168-derived tumors to
α-TGFβ and α-PD-1 therapies.
Of the six SCC lines studied, CCK168 is most sensitive
to combinatorial immunotherapy but, even in this line,
tumor responses are heterogeneous and only 60% of
a
b
Fig. 5 Treg depletion synergizes with α-PD-1 but not α-TGFβ in tumor regression and long term survival. CCK168 tumors were treated as in Fig.
1b, except that 24 h prior to the first therapeutic drug dose, mice received intraperitoneal injection of an IgG control or α-CD25+ cell-depleting
antibody. a) and b) Kaplan Meier survival plots for CCK168 tumor-bearing mice using using 2000mm3 tumor size as cut off for survival. P < 0.05 = *,
p < 0.01 = ** Gehan-Breslow-Wilcoxon test
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Fig. 6 α-PD-1 therapy induces pSmad3 signaling in CCK168 tumors to enhance EMT and suppress gene expression of antigen presenting
machinery. a-f CCK168 tumor-bearing mice were treated either with α-PD-1 monotherapy or IgG control antibodies on day 0 and 4. As indicated
in (a), on day 8, the α-PD-1 treated group were randomly split into two further groups and treated with either control IgG or α-TGFβ monotherapy, and all
tumors were harvested 2 h later for pSmad3 immunofluorescence staining. b and c quantification of the three arms of the experiment b as percentage of
DAPI+ nuclei stained with pSmad3 and c intensity of pSmad3 staining per nucleus. d-f representative images of pSmad3 immunofluorescence staining.
Note rim of tumor in α-TGFβ treated sample f shows dramatically reduced pSmad3 staining. g, h CCK168 tumor-bearing mice were treated with α-PD-1 or
α-TGFβ on day 0 and day 4, and analyzed by pSmad3 immunofluorescence on day 8. i-n CCK168 cells grown in vitro were treated with TGFβ and/or α-
TGFβ antibodies. I-m) phase contrast analysis shows reversible TGFβ-induced EMT. n RNA from cultures shown in (l-m) was extracted and subjected to
qRT-PCR to quantify gene expression of components of the tumor cell antigen presentation machinery, Mhc1, B2M (β2-microglobulin), Tap1 and Tap2.
* = P < 0.05, **** = P < 0.0001; Unpaired two-tailed Student’s T test
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tumors achieve CR following α-PD-1/α-TGFβ combin-
ation therapy at the doses used. The extent of immune
cell infiltration exhibited considerable heterogeneity be-
tween tumors derived from CCK168 cells (Fig. 4). We
therefore sought to determine whether intratumoral
leukocyte profiles could distinguish productive versus
non-productive tumor responses. We undertook unsuper-
vised hierarchical cluster analysis the CCK168 tumor im-
mune cell profile data generated by flow cytometry
following 8 days of IgG or drug treatment. This analysis
revealed that responding tumors tended to segregate




Fig. 7 Heterogeneous mechanisms of tumor response to α-PD-1 and α-TGFβ therapy. a Unsupervised hierarchical clustering of indicated immune
cell sub-populations in tumors after treatment with control IgG, α-PD-1, α-TGFβ, or combination therapy. Tumors were classified into responders
(light green), stable disease (dark green) or non-responders (red) as described in Methods (colored horizontal bar). Responding mice tend to
cluster into two groups that we label Responding Cluster A and Responding Cluster B, while non-responding mice tend to cluster into a third
group (Cluster C). Mice in the two responding groups had significantly better outcomes than mice in the nonresponding cluster (p = 0.02, Fisher’s
Exact test). Immune profiles of tumor infiltrates in Cluster B are characterized by high T cell levels and relatively low LyC6–macrophages (TAM2s),
while those in Cluster A are characterized by low levels of all immune cell subtypes except CD4+ T cells, in particular high CD4 + FoxP3–CD25– (T
helper) cells. b Unsupervised hierarchical cluster analysis undertaken according to expression of a Treg transcriptomic signature in pre-treatment
human melanoma samples from patients treated with α-PD-1 (see Supplementary Methods). Transcriptomic data from pre-treatment melanoma
samples [12] were subjected to unsupervised hierarchical cluster analysis based on gene transcripts whose expression correlates with FoxP3
expression in CD4+ cells. Human tumors responses were classified according to Hugo et al. 2016 [12] and the original tumor IDs are presented at
the base of the figure. Samples from patients exhibiting a response, in particular CR, tended to cluster together (P = 0.005, Fisher’s Exact test) and
to have reduced expression of FoxP3-associated genes. c,d) Each SCC line, in order of decreasing TML, CCK168, CCK169, CCK62, CCK166, GEK1425,
GEK1428, was used to induced tumors in mice, and treated with α-PD-1 or control IgG on Day 0 and Day 4 (Fig. 1b). On day 8, tumors were
harvested for flow cytometric analysis of immune cells. c CD4+ T cells per total CD45+, d CD8+ cytotoxic T cells per total CD45+
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Cluster B (Fig. 7a). Mice in these two “responding clus-
ters” had significantly better outcomes than mice in
Cluster C, the “nonresponding cluster” (p = 0.02, Fish-
er’s Exact test). Cluster B, the larger of the responder
groups, was characterized by higher CD8+ T cell num-
bers, especially activated CD8 + ICOS+ and CD8 +
CTLA4+ T cells, higher inflammatory Ly6Chi TAM num-
bers, but lower levels of Ly6Clo TAMs. The second,
smaller responding cluster, Cluster A, had relatively low
levels of all immune cell types except for highly prevalent
CD4+ T cells (CD4 + FoxP3-CD25-). The third cluster of
predominantly non-responding tumors, Cluster C, was
characterized by lower levels of CD8+ cells and Ly6Chi
TAMs, but higher levels of CTLA4 +Tregs, Ly6Clo TAMs
and a high Ly6Clo/Ly6Chi TAM ratio, compared to
responding Clusters A and B (Fig. 7a). Thus it appears that
there are two classes of responsive CCK168 SCCs, those
with high and those with low CD8+ cytotoxic T cell infil-
tration, with the latter class having a higher CD4+ Th cell
content that may be particularly responsive to α-TGFβ.
To address the translational relevance of Tregs as a
biomarker of resistance to α-PD-1 therapy, we investi-
gated the link between pretreatment intratumoral acti-
vated Treg levels and clinical response to α-PD-1 in
melanoma patients. We interrogated transcriptomic data
from a study of 38 pembrolizumab (α-PD-1) pretreatment
melanoma tumors for which clinical outcomes data were
available (21 responding versus 17 non-responding) [13].
Unsupervised hierarchical cluster analysis based on a
Foxp3-associated transcriptional CD4+ T cell signature
[37] showed that tumors from patients with subsequent
CR on clinical follow up clustered together based on lower
expression of this Treg signature (Fig. 7b, p = 0.005).
CD4+ T cell content distinguishes responding from non-
responding SCC tumor lines
Having established the heterogeneity of tumor responses
to therapy within one tumor line, CCK168, we next ad-
dressed which determinants across the SCC panel, other
than mutation load, might also associate with tumor re-
jection after α-TGFβ or α-TGFβ plus α-PD-1 combin-
ation therapy. All six lines expressed comparable levels
of total TGFβ1 and TGFβ2 proteins, with little expres-
sion of TGFβ3 in vitro, as determined by ELISA (data
not shown). Moreover, each line showed sensitivity to
TGFβ in vitro as demonstrated by activation of pSmad2/
3 in response to TGFβ (data not shown).
Since no obvious in vitro characteristic distinguished
the six SCC lines from one another, and the only parameter
that appears to associate with tumor response to immuno-
therapy was TML, we asked whether distinct immune cell
subsets within pre-treatment or α-PD-1-treated tumors dis-
tinguish responsive from non-responsive SCC lines. IHC
analysis of intra-tumoral T and myeloid cell populations
(Fig. S10) distinguished two tumor classes according to in-
filtrating CD45+ leukocyte and CD3+ T lymphocyte con-
tent. GEMM-derived tumors, GEK1425 and GEK1428, and
the non-responsive carcinogen-induced carcinoma, CCK62,
showed very little infiltration by T cells (CD3+ or CD8a+)
(Fig. S10), and this was largely unaltered by therapy. Con-
versely, levels of CD3+ and CD8a +T cells were higher in
the responsive lines CCK168 (Figs. 2a, 4a, Additional file 3:
FigureS10) and CCK169 SCCs (Fig. S10), and further in-
duced by combination therapy. Paradoxically, CCK166 tu-
mors that are resistant to immunotherapy and have the
lowest TML of the chemically-induced SCC subset, never-
theless had CD45+, CD3+ and CD8+ T cell levels compar-
able to those of the two high TML, drug-responsive SCC
lines. CD45+, CD3+ and CD8+ cell levels also increased in
CCK166 in response to combinatorial therapy (Fig. S10).
This demonstrates the lack of correlation between tumor
immune cell infiltrate and anti-tumor response, even in this
small panel of SCCs.
In order to consolidate and extend this finding, we
compared levels of intra-tumoral CD45+ leukocytes,
CD8+ cytotoxic T cells, total CD4+ T cells, Foxp3+
Tregs, and myeloid cells by multi-color flow cytometry
(Fig. 7 c,d). The only pre-treatment parameter we found
to associate with response to combination therapy was
total CD4+ T cell content. Control-treated CCK168 and
CCK169 tumors, had a significantly greater CD4+ T cell
content than tumors of the unresponsive tumor lines
(Fig. 7c, p = 0.001). This observation is consistent with
the finding of a subcategory of CCK168 drug-responsive
tumors marked by high CD4+ T cell levels (Fig. 7a), that
may be an important determinant of synergy between
α-PD-1 and α-TGFβ in SCCs.
Discussion
In the current study, we present a novel panel of
chemically-induced and GEMM-derived cSCC tumor lines
and show that only those with high TML respond to im-
munotherapy. We also make the novel finding that in such
SCCs, α-PD-1 therapy not only induces cytotoxic T cell
activity, but also induces a competing TGFβ-driven im-
munosuppressive program that restrains its anti-tumor ac-
tivity. We demonstrate that α-PD-1 therapy results in
skewing of the CD4+ Teff/Treg balance in favor of immuno-
suppressive Tregs, and these Tregs functionally limit the
anti-tumor activity of α-PD-1 in CCK168 SCCs. We also
demonstrate that α-PD-1 therapy enhances TGFβ-Smad3
signaling within tumor cells, that contributes to EMT.
α-TGFβ monotherapy is consequently more efficacious (20%
CR) than α-PD-1 monotherapy (< 3% CR), as it targets both
Tregs and tumor cell EMT while also stimulating the effector
arms of both the innate and adaptive immune systems. Im-
portantly, the two drugs synergize when used in combination
to provide 60% CR in established CCK168 tumors.
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Recent analyses of pre-treatment immune-excluded
urothelial cancers and human melanomas, revealed en-
richment for a transcriptomic signature of TGFβ signal-
ing [16] and TGFβ-driven mechanisms, such as EMT
and immunosuppression [13], in patients with poor clin-
ical outcomes following subsequent blockade of the
PD-1/PDL-1 axis. Our current findings are not incon-
sistent with these clinical studies, but go farther to show
that α-PD-1 monotherapy itself promotes increased
tumor cell TGFβ signaling and elevates the immunosup-
pressive Treg/Th balance, consequently limiting the effi-
cacy of this checkpoint blockade drug. This unexpected
activity of α-PD-1 in inducing the TGFβ signaling axis
may contribute to the recently described clinical phe-
nomenon of α-PD-1 super-progressors following check-
point blockade therapy that has been observed in several
cancer types [3–5].
Mariathasan et al. [16] and Tauriello et al. [17] recently
demonstrated that stromal cancer-associated fibroblasts
(CAFs) are the major cell source and responders to
TGFβ signaling in colon and urothelial carcinomas, re-
spectively. These studies suggest that CAFs create an im-
munosuppressive barrier preventing penetration of T cells
into the tumor proper. However, in the immune-infiltrated
CCK168 model, CAFs do not appear to play such a role
since most non-immune cells are tumor cells rather than
CAFs, as shown by expression of cytokeratin K8 and K18
(not shown). Nevertheless, by virtue of TGFβ-induced
EMT, tumor cells themselves may acquire a CAF-like
phenotype and fibroblastic immunosuppressive functions.
Under the influence of α-PD-1, elevated pSmad3 may drive
EMT towards a more extreme myofibroblast phenotype, re-
duced expression of antigen presentation machinery and
changes in the secreted cytokine and extracellular matrix
profiles that suppress tumor immune recognition. Indeed,
histological analysis of CCK168 tumors suggests a more
overt spindle phenotype after α-PD-1 therapy and reversal
of this effect after α-TGFβ therapy, and in vitro data dem-
onstrate reversible activity of TGFβ in induction of
CCK168 EMT and suppression of expression of compo-
nents of the antigen presentation machinery.
The mechanism of α-PD-1-elevated pSmad3 signaling
in tumor cells is unlikely direct, since CCK168 cells ex-
press no PD-1 and only low levels of PD-L1 and PD-L2
(data not shown). In the transgenic adenocarcinoma of
mouse prostate (TRAMP) model, activated effector CD4+
T cells have been reported to release active TGFβ1 [38].
Moreover, according to conventional wisdom, Tregs are a
major source of TGFβ. α-PD-1 therapy may therefore en-
hance TGFβ activity through its activation of CD4+ T
cells, both Tregs and Th1 cells. TAMs and/or DCs may
also release and/or activate TGFβ that drives Treg differ-
entiation [39]. Notably, PD-1 is expressed on mouse and
human TAMs [40], but the consequence of PD-1 blockade
on secretion or activation of TGFβ has not been investi-
gated. The elevated intratumoral Treg/Th balance that we
observe following α-PD-1 monotherapy may be due to
prevention of Treg anergy by blockade of PD-1
expressed on Treg cells. Alternatively, α-PD-1 may in-
crease Treg differentiation indirectly, in response to ac-
tive TGFβ released from other cellular or extracellular
sources, such as activated CD4+ Th cells [38] or im-
munosuppressive myeloid cells. Precedent for the direct
activation of Tregs by α-PD1 comes from studies in
non-neoplastic disease models, such as those of infec-
tion and allergy, where PD-1 plays a role in inducing
Treg anergy [41, 42].
High pre-treatment tumor CD4+ T cell content is
the only parameter, apart from high TML, that associ-
ates with immunotherapy responses in two of the
panel of six SCC tumor lines studied here. CD4+ T
cells, unlike the cytotoxic T cell lineage, show consid-
erable plasticity in differentiation, such that Tregs are
capable of re-differentiation towards an inflammatory
Th phenotype [43, 44] that may be modulated by
α-TGFβ immunotherapy. α-TGFβ or a combination of
α-PD-1 with α-TGFβ might therefore be indicated for
that category of patients with a high intratumoral
CD4+ T cell or Treg content. Such an intratumoral
immune cell profile has been reported for SCC-HN
[45], which also bear high TMLs [6] and have been
reported to undergo super-progression in response to
a-PDL-1 therapy [5].
Additive, synergistic and redundant anti-tumor in-
teractions between TGFβ signaling and the PD-1/
PD-L1 axis [18–22] may be influenced by host genetic
background [46–48]. Characterization of such interac-
tions and development of predictive biomarkers for
response to α-PD-1/α-TGFβ therapy is therefore of
high priority. The panel of syngeneic carcinomas pre-
sented here, comprising cell lines with a range of mu-
tation burdens and immune cell profiles, all on the
same FVB genetic background, and driven by the
most common oncogenic signaling pathway, Kras,
provides additional opportunities to investigate the
disparate mechanisms of innate and acquired resistance
to immunotherapies that may be encountered in the
clinic. Notably, the potent and specific TGFβ blocking
antibodies used in our studies have entered clinical trial in
combination with α-PD-1 for oncology (NCT02947165),
and additional drugs that impact this pathway [15] may
also prove effective in combinatorial immunotherapy with
checkpoint blockade drugs.
Conclusions
We show that α-PD-1 not only initiates a tumor rejection
program, but can induce a competing TGFβ-driven
immuno-suppressive program in SCCs. α-PD-1 monotherapy
Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer            (2019) 7:62 Page 13 of 15
skews the CD4+T cell balance in favor of immunosuppres-
sive Tregs, and elevate pSmad3 signaling within tumor cells,
features that are blocked by α-TGFβ therapy. In SCCs, TGFβ
blockade acts through both tumor cell autonomous and
immune-mediated mechanisms to stimulate anti-tumor im-
munity and alleviate α-PD-1 resistance. This study forms the
basis for a clinical trial of α-TGFβ/α-PD-1 combination ther-
apy (NCT02947165).
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